Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F R Noriega

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
The Journal of Parasitology|June 1, 1988
Toxoplasma gondii maintenance in tissue culture: a new efficient method for culturing RH tachyzoitesF R Noriega, W E Hauser
Gut|April 1, 1997
Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivoA Fasano, F R Noriega, F M Liao, et al.
Infection and Immunity|January 1, 1996
Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coliF R Noriega, G Losonsky, J Y Wang, et al.
Infection and Immunity|July 19, 2000
Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909J Y Wang, F R Noriega, J E Galen, et al.
The Journal of Infectious Diseases|November 1, 1995
Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypesF R Noriega, F M Liao, S B Formal, et al.
Vaccine|March 16, 2000
DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxinR J Anderson, M F Pasetti, M B Sztein, et al.
Clinical Immunology (Orlando, Fla.)|July 22, 1999
Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responsesM F Pasetti, R J Anderson, F R Noriega, et al.
Infection and Immunity|August 1, 1996
Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccineF R Noriega, G Losonsky, C Lauderbaugh, et al.
Infection and Immunity|January 23, 1999
Strategy for cross-protection among Shigella flexneri serotypesF R Noriega, F M Liao, D R Maneval, et al.
Infection and Immunity|November 1, 1994
Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccineF R Noriega, J Y Wang, G Losonsky, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
The Journal of Parasitology|June 1, 1988
Toxoplasma gondii maintenance in tissue culture: a new efficient method for culturing RH tachyzoitesF R Noriega, W E Hauser
Gut|April 1, 1997
Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivoA Fasano, F R Noriega, F M Liao, et al.
Infection and Immunity|January 1, 1996
Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coliF R Noriega, G Losonsky, J Y Wang, et al.
Infection and Immunity|July 19, 2000
Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909J Y Wang, F R Noriega, J E Galen, et al.
The Journal of Infectious Diseases|November 1, 1995
Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypesF R Noriega, F M Liao, S B Formal, et al.
Vaccine|March 16, 2000
DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxinR J Anderson, M F Pasetti, M B Sztein, et al.
Clinical Immunology (Orlando, Fla.)|July 22, 1999
Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responsesM F Pasetti, R J Anderson, F R Noriega, et al.
Infection and Immunity|August 1, 1996
Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccineF R Noriega, G Losonsky, C Lauderbaugh, et al.
Infection and Immunity|January 23, 1999
Strategy for cross-protection among Shigella flexneri serotypesF R Noriega, F M Liao, D R Maneval, et al.
Infection and Immunity|November 1, 1994
Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccineF R Noriega, J Y Wang, G Losonsky, et al.
Pageof 2